JTK 109Alternative Names: JTK-109
Latest Information Update: 06 Oct 2003
At a glance
- Originator Japan Tobacco
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 06 Oct 2003 Discontinued - Phase-I for Hepatitis C (PO)
- 06 Oct 2003 Discontinued - Phase-I for Hepatitis C in Japan (PO)
- 02 Dec 2002 Phase-I clinical trials in Hepatitis C (PO)